Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 1,501–1,600 of 1,689
Panza, F., Solfrizzi, V., Torres, F., Mastroianni, F., Colacicco, A. M., Basile, A. M., Capurso, C., D'Introno, A., Del Parigi, A., & Capurso, A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01447-6 · Cited by 33
Matsunaga, A., & Saito, T. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0918-1 · Cited by 33
Cholesterol and Alzheimer's disease
Wolozin, B. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300525 · Cited by 33
Human APOE genotype affects intraneuronal A 1-42 accumulation in a lentiviral gene transfer model
Zhao, W., Dumanis, S. B., Tamboli, I. Y., Rodriguez, G. A., Jo LaDu, M., Moussa, C. E. H., & William Rebeck, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt525 · Cited by 32
Apolipoprotein E ε4-related thickening of the cerebral cortex modulates selective attention
Espeseth, T., Westlye, L. T., Walhovd, K. B., Fjell, A. M., Endestad, T., Rootwelt, H., & Reinvang, I. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.027 · Cited by 32
“Inheritance of the apolipoprotein E (APOE) 4 genotype is associated with increased risk of developing Alzheimer’s disease (AD) and younger age of AD onset (Corder et al., 1993; Raber et al., 2004).”
BackgroundVergallo, A., Houot, M., Cavedo, E., Lemercier, P., Vanmechelen, E., De Vos, A., Habert, M., Potier, M., Dubois, B., Lista, S., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.001 · Cited by 32
“To our knowledge for the first time, we performed both cross-sectional and longitudinal explorative studies to investigate whether key biological factors such as sex [16,17], APOE ε4 allele [18], and age may influence BACE1 enzyme expression, in terms of enzyme plasma concentrations, in a monocenter cohort of cognitiv…”
BackgroundPreman, P., Moechars, D., Fertan, E., Wolfs, L., Serneels, L., Shah, D., Lamote, J., Poovathingal, S., Snellinx, A., Mancuso, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00162-7 · Cited by 32
“…E was identi fi ed 30 years ago as the major genetic risk factor for Alzheimer ’ s Disease (AD) at the population level (Bennett et al, 2009; Corder et al, 1993; Strittmatter et al, 1993) while the APOE2 variant was the fi rst identi fi ed protective allele against AD (Corder et al, 1994;…”
Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain
Fujita, S. C., Sakuta, K., Tsuchiya, R., & Hamanaka, H. (1999) · Neuroscience Research · doi:10.1016/s0168-0102(99)00075-9 · Cited by 32
“…after epidemiological analyses established that apoE4, the second most common allelic isoform of apoE in humans after apoE3, is associated with an increased risk of both sporadic as well as familial Alzheimer’s disease across many ethnic populations (Corder et al., 1993; Poirier et al., 1993b).”
BackgroundDafnis, I., Tzinia, A. K., Tsilibary, E. C., Zannis, V. I., & Chroni, A. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.013 · Cited by 32
“ApoE4 is a major genetic risk factor for AD since 40% of all patients have at least one ε4 allele (Corder et al., 1993) and it increases the occurrence and lowers the age of onset of sporadic AD (Corder et al.”
BackgroundFragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer
Petros, A. M., Korepanova, A., Jakob, C. G., Qiu, W., Panchal, S. C., Wang, J., Dietrich, J. D., Brewer, J. T., Pohlki, F., Kling, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00178 · Cited by 32
The distribution of cerebrovascular amyloid in Alzheimer’s disease varies with ApoE genotype
Trembath, D., Ervin, J. F., Broom, L., Szymanski, M., Welsh-Bohmer, K., Pieper, C., & Hulette, C. M. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0162-9 · Cited by 31
“4 allele is a risk factor for late onset AD, with the age of onset shifting to a younger age with each additional 4 allele [10].”
BackgroundAsaro, A., Sinha, R., Bakun, M., Kalnytska, O., Carlo-Spiewok, A.-S., Rubel, T., Rozeboom, A., Dadlez, M., Kaminska, B., Aronica, E., et al. (2021) · Journal of Cell Science · doi:10.1242/jcs.258894 · Cited by 31
Ercoli, L., Siddarth, P., Huang, S.-C., Miller, K., Bookheimer, S. Y., Wright, B. C., Phelps, M. E., & Small, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.442 · Cited by 31
Self-citationCDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
Ahmad, S., Milan, M. D. C., Hansson, O., Demirkan, A., Agustin, R., Sáez, M. E., Giagtzoglou, N., Cabrera-Socorro, A., Bakker, M. H. M., Ramirez, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65038-5 · Cited by 31
“The levels of CSF AD-related biomarkers (Aβ42, total and phosphorylated tau [t-Tau and p-Tau181]) were analyzed at Amsterdam UMC as part of the routine diagnostic procedure using commercially available kits (Innotest Aβ(1-42), total Tau, phospho-Tau(181 P); Fujirebio, Ghent, Belgium)10,24.”
MethodApolipoprotein-E forms dimers in human frontal cortex and hippocampus
Elliott, D. A., Halliday, G. M., & Garner, B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-23 · Cited by 31
“ApoE4 is a major genetic risk factor for late-onset Alzheimer’s disease (AD) whereas apoE2 is associated with decreased AD risk [4,5].”
BackgroundThe ε4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease
Kljajevic, V., Meyer, P., Holzmann, C., Dyrba, M., Kasper, E., Bokde, A. L. W., Fellgiebel, A., Meindl, T., Hampel, H., Teipel, S., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.008 · Cited by 30
“The exact mechanism by which APOE ε4 contributes to the disease remains unclear, but evidence suggests that increasing number of APOE ε4 alleles increases the risk of AD while reducing the mean age of onset [7].”
Argyri, L., Dafnis, I., Theodossiou, T. A., Gantz, D., Stratikos, E., & Chroni, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538124 · Cited by 30
“ApoE4 is a major genetic risk factor for late-onset AD (LOAD) because 40% of all patients have at least one 4 allele (4).”
BackgroundOpposing Roles of apolipoprotein E in aging and neurodegeneration
Hudry, E., Klickstein, J., Cannavo, C., Jackson, R., Muzikansky, A., Gandhi, S., Urick, D., Sargent, T., Wrobleski, L., Roe, A. D., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900325 · Cited by 30
“APOE, the major apolipoprotein of the brain and most important genetic contributor to the sporadic form of AD (Wisniewski & Frangione, 1992; Corder et al, 1993, 1994; West et al, 1994; Hyman et al, 1996; Lippa et al, 1997), is a well-established partner of amyloid β peptides and has been shown to…”
Nemergut, M., Marques, S. M., Uhrik, L., Vanova, T., Nezvedova, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00620-9 · Cited by 30
Langella, S., Barksdale, N. G., Vasquez, D., Aguillon, D., Chen, Y., Su, Y., Acosta-Baena, N., Acosta-Uribe, J., Baena, A. Y., Garcia-Ospina, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40775-z · Cited by 30
“APOE e4 haslong been associated withincreasedrisk andearlier ageof onset for sporadic AD 1,2,17 – 20 .”
LaDu, M. J., Munson, G. W., Jungbauer, L., Getz, G. S., Reardon, C. A., Tai, L. M., & Yu, C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.11.005 · Cited by 30
“ApoE modulates risk for AD, with ε2/2 decreasing risk 4-fold and ε4/4 increasing risk 12 fold [1-3].”
BackgroundEvidence for three loci modifying age‐at‐onset of Alzheimer's disease in early‐onset PSEN2 families
Marchani, E. E., Bird, T. D., Steinbart, E. J., Rosenthal, E., Yu, C., Schellenberg, G. D., & Wijsman, E. M. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31072 · Cited by 29
“The more-common APOE e4 allele is neither necessary nor sufficient to cause LOAD [Corder et al., 1993; Strittmatter et al., 1993; Evans et al., 1997; Slooter et al., 1998], and variation within APOE is estimated to explain only 4–15% of the variance in age-at-onset [Bennett et al., 1995; Slooter et…”
BackgroundInfluentialSome evolutionary perspectives on Alzheimer's disease pathogenesis and pathology
Glass, D. J., & Arnold, S. E. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2408 · Cited by 29
“A number of genes have been associated with sporadic AD such as A2M, FE65, GLUR5, and SORL1, among others [7–12]), but so far, the only unequivocal risk gene is apolipoprotein E (APOE) [13,14].”
BackgroundHan, S.-H., Kim, J. S., Lee, Y., Choi, H., Kim, J.-W., Na, D. L., Yang, E. G., Yu, M.-H., Hwang, D., Lee, C., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.028639 · Cited by 29
Tarawneh, R. (2023) · Biomolecules · doi:10.3390/biom13050830 · Cited by 29
Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease
Liu, L., & Caselli, R. J. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.006 · Cited by 29
Differential effects of apoE4 and activation of ABCA1 on brain and plasma lipoproteins
Boehm-Cagan, A., Bar, R., Harats, D., Shaish, A., Levkovitz, H., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166195 · Cited by 29
Chan, E. S., Chen, C., Cole, G. M., & Wong, B.-S. (2015) · Scientific Reports · doi:10.1038/srep13842 · Cited by 29
Wang, X., Li, H., Sheng, Y., He, B., Liu, Z., Li, W., Yu, S., Wang, J., Zhang, Y., Chen, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116071 · Cited by 29
Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation
Levi, O., Lütjohann, D., Devir, A., Von Bergmann, K., Hartmann, T., & Michaelson, D. M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03441.x · Cited by 29
“Alzheimer’s disease (AD) is associated with genetic risk factors, of which the allele E4 of apolipoprotein E (apoE4) is the most prevalent (Corder et al. 1993; Saunders et al. 1993; Roses 1996).”
BackgroundLai, M. K. P., Tsang, S. W. Y., Garcia-Alloza, M., Minger, S. L., Nicoll, J. A. R., Esiri, M. M., Wong, P. T.-H., Chen, C. P. L.-H., Ramírez, M. J., & Francis, P. T. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.016 · Cited by 29
The involvement of microglia in Alzheimer's disease: a new dog in the fight
Moore, Z., Taylor, J. M., & Crack, P. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14546 · Cited by 29
Apo E: The role of conserved residues in defining function
Frieden, C. (2015) · Protein Science · doi:10.1002/pro.2597 · Cited by 29
Minami, S. S., Sung, Y. M., Dumanis, S. B., Chi, S. H., Burns, M. P., Ann, E.-J., Suzuki, T., Turner, R. S., Park, H.-S., Pak, D. T. S., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-138123 · Cited by 28
Tran, K. M., Kwang, N. E., Butler, C. A., Gomez-Arboledas, A., Kawauchi, S., Mar, C., Chao, D., Barahona, R. A., Da Cunha, C., Tsourmas, K. I., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00793-x · Cited by 28
“Homozygous APOE4 individuals have a 6 to 18-fold increase in AD risk compared to APOE2/3 individuals [9, 10].”
Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins
Strickland, M. R., Rau, M. J., Summers, B., Basore, K., Wulf, J., Jiang, H., Chen, Y., Ulrich, J. D., Randolph, G. J., Zhang, R., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.018 · Cited by 28
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2019) · doi:10.1101/19012021 · Cited by 28
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
“Mouse J20 line of hAPPFAD and overexpressing APOE 272-299 ApoE4 (1-271)1 (N-terminal) Decreases Aβ clearance and increases Aβ deposition In vivo/ In vitro Full-length ApoE3 and ApoE4 expressing mice were able to stimulate Aβ clearance Bien-Ly et al.”
BackgroundInfluentialCarter, A. Y., Letronne, F., Fitz, N. F., Mounier, A., Wolfe, C. M., Nam, K. N., Reeves, V. L., Kamboh, H., Lefterov, I., & Koldamova, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172161 · Cited by 28
“The inheritance of APOE ε 4 allele is the major genetic risk factor for late-onset Alzheimer disease (LOAD) [1].”
Assessment of APOE in atypical parkinsonism syndromes
Sabir, M. S., Blauwendraat, C., Ahmed, S., Serrano, G. E., Beach, T. G., Perkins, M., Rice, A. C., Masliah, E., Morris, C. M., Pihlstrom, L., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.016 · Cited by 28
Saul, A., & Wirths, O. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9674-4 · Cited by 28
“Carrying one or two ApoE ε4 alleles (ApoE4) drastically increases the probability to develop AD, while carrying an ApoE2 allele even confers a certain degree of protection [1].”
BackgroundHatters, D. M., Voss, J. C., Budamagunta, M. S., Newhouse, Y. N., & Weisgraber, K. H. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.12.040 · Cited by 28
Shuvaev, V. V., Laffont, I., & Siest, G. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01285-5 · Cited by 27
Riviere, M., Langbaum, J. B., Turner, R. S., Rinne, J. O., Sui, Y., Cazorla, P., Ricart, J., Meneses, K., Caputo, A., Tariot, P. N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13532 · Cited by 28
Alvarez, V., Corao, A. I., Alonso-Montes, C., Sánchez-Ferrero, E., De Mena, L., Morales, B., García-Castro, M., & Coto, E. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13305 · Cited by 27
“Although several loci have been involved in LOAD-risk, to date only the apolipoprotein E-ε 4 allele has been clearly established as a genetic risk factor [3,13,16,31,33].”
Impaired secretion of apolipoprotein E2 from macrophages
Fan, D., Qiu, S., Overton, C. D., Yancey, P. G., Swift, L. L., Jerome, W. G., Linton, M. F., & Fazio, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611754200 · Cited by 27
Su, R., Han, Z.-Y., Fan, J.-P., & Zhang, Y.-L. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-0131-0 · Cited by 27
Kornecook, T. J., McKinney, A. P., Ferguson, M. T., & Dodart, J. ‐. (2010) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2009.00545.x · Cited by 27
“It is well established that the ε4 allele is a major genetic risk factor for Alzheimer’s disease (AD) (Corder et al. 1993; Saunders et al. 1993).”
BackgroundCerebrospinal fluid lipoproteins in Alzheimer's disease
Bassett, C. N., Montine, K. S., Neely, M. D., Swift, L. L., & Montine, T. J. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000815)50:4<282::aid-jemt6>3.0.co;2-t · Cited by 27
Amyloid plaque-associated oxidative degradation of uniformly radiolabeled arachidonic acid
Furman, R., Murray, I. V. J., Schall, H. E., Liu, Q., Ghiwot, Y., & Axelsen, P. H. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00316 · Cited by 26
Riggs, J. E., & Keefover, R. W. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540200024011 · Cited by 26
Wang, Z., Dai, Z., Shu, H., Liu, D., Guo, Q., He, Y., & Zhang, Z. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160724 · Cited by 26
“The apolipoprotein E (APOE) ε 4 allele is the most common susceptibility gene for AD [5] and influ-ences the course of disease by increasing the risk for developing AD and lowering the age at disease onset [6, 7].”
Association of refractory complex partial seizures with a polymorphism of ApoE genotype
Sporiš, D., Sertic, J., Henigsberg, N., Mahovic, D., Bogdanovic, N., & Babic, T. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00500.x · Cited by 26
“Apolipoprotein E first came to the attention of neurologists as a result of the genetic association between ApoE ε4 and a late onset of Alzheimer's disease [6].”
BackgroundGünaydin, C., Sondhi, D., Kaminsky, S. M., Lephart, H. C., Leopold, P. L., Hackett, N. R., Khanna, R., & Crystal, R. G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.003 · Cited by 26
Anatomic survey of seeding in Alzheimer’s disease brains reveals unexpected patterns
Stopschinski, B. E., Del Tredici, K., Estill-Terpack, S.-J., Ghebremedhin, E., Yu, F. F., Braak, H., & Diamond, M. I. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01255-x · Cited by 26
Chroni, A., Pyrpassopoulos, S., Thanassoulas, A., Nounesis, G., Zannis, V. I., & Stratikos, E. (2008) · Biochemistry · doi:10.1021/bi800469r · Cited by 26
“Being homozygous for the ε4 allele increases the risk of AD 4-fold and lowers the age of onset of late-onset AD (5).”
BackgroundApolipoproteins E and C1 and brain morphology in memory impaired elders
Serra-Grabulosa, J. M., Salgado-Pineda, P., Junqué, C., Solé-Padullés, C., Moral, P., López-Alomar, A., López, T., López-Guillén, A., Bargalló, N., Mercader, J. M., et al. (2003) · Neurogenetics · doi:10.1007/s10048-002-0142-8 · Cited by 26
“The apolipoprotein E (APOE) E4 variant (APOE*4) is a major genetic risk factor for Alzheimer’s disease (AD) [13, 14, 15 ] and forms a cluster with the genes encoding the apolipoproteins C1 (APOC1) and C2. Previous studies reported an association of the APOC1 allele (the insertion allele) or the haplotypes including th…”
BackgroundApolipoprotein E, Alzheimer disease, and African Americans
Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.161 · Cited by 26
Serum α-tocopherol, concurrent and past vitamin E intake, and mild cognitive impairment
Dunn, J. E., Weintraub, S., Stoddard, A. M., & Banks, S. (2007) · Neurology · doi:10.1212/01.wnl.0000255940.13116.86 · Cited by 25
Diabetic retinopathy and dementia association, beyond diabetes severity
Lee, C. S., Krakauer, C., Su, Y.-R., Walker, R. L., Blazes, M., McCurry, S. M., Bowen, J. D., McCormick, W. C., Lee, A. Y., Boyko, E. J., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.12.003 · Cited by 25
Apolipoprotein CI Knock-Out Mice Display Impaired Memory Functions
Berbée, J. F. P., Vanmierlo, T., Abildayeva, K., Blokland, A., Jansen, P. J., Lütjohann, D., Gautier, T., Sijbrands, E., Prickaerts, J., Hadfoune, M., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100576 · Cited by 25
An Alzheimer’s-disease-protective APOE mutation
Zalocusky, K. A., Nelson, M. R., & Huang, Y. (2019) · Nature Medicine · doi:10.1038/s41591-019-0634-9 · Cited by 25
Age-at-Onset and APOE -Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease
Smirnov, D. S., Galasko, D., Hiniker, A., Edland, S. D., & Salmon, D. P. (2021) · Neurology · doi:10.1212/wnl.0000000000011772 · Cited by 25
Back to the origins: Human brain organoids to investigate neurodegeneration
Faravelli, I., Costamagna, G., Tamanini, S., & Corti, S. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146561 · Cited by 25
Budny, V., Ruminot, I., Wybitul, M., Treyer, V., Barros, L. F., & Tackenberg, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03550-w · Cited by 25
“APOE4 increases the risk of developing AD by 2.5 – 4-fold in heterozygous and 12 – 15-fold in homozygous carriers [6 – 11].”
InfluentialAxl receptor tyrosine kinase is a regulator of apolipoprotein E
Zhao, W., Fan, J., Kulic, I., Koh, C., Clark, A., Meuller, J., Engkvist, O., Barichievy, S., Raynoschek, C., Hicks, R., et al. (2020) · Molecular Brain · doi:10.1186/s13041-020-00609-1 · Cited by 25
Martin-Estebane, M., & Gomez-Nicola, D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00149 · Cited by 25
Qureshi, Y. H., Baez, P., & Reitz, C. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00262-20 · Cited by 25
Use of Genetic Variation as Biomarkers for Alzheimer's Disease
Reitz, C., & Mayeux, R. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04945.x · Cited by 24
Georgiadou, D., Chroni, A., Vezeridis, A., Zannis, V. I., & Stratikos, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027037 · Cited by 24
Staurenghi, E., Leoni, V., Lo Iacono, M., Sottero, B., Testa, G., Giannelli, S., Leonarduzzi, G., & Gamba, P. (2022) · Antioxidants · doi:10.3390/antiox11112168 · Cited by 24
“The strongest genetic risk factor for sporadic AD is the presence of the ε4 allele of the apolipoprotein E (ApoE) gene, the major apolipoprotein involved in brain cholesterol transport [2,3].”
BackgroundScreening and Evaluation of Deleterious SNPs in APOE Gene of Alzheimer’s Disease
Masoodi, T. A., Al Shammari, S. A., Al-Muammar, M. N., & Alhamdan, A. A. (2012) · Neurology Research International · doi:10.1155/2012/480609 · Cited by 24
“…May N. Al-Muammar, and Adel A. Alhamdan Health Care Development for Elderly Research Chair, Community Health Sciences Department, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia Correspondence should be addressed to Tariq Ahmad Masoodi,…”
BackgroundInfluentialHuebbe, P., Bilke, S., Rueter, J., Schloesser, A., Campbel, G., Glüer, C.-C., Lucius, R., Röcken, C., Tholey, A., & Rimbach, G. (2024) · Aging and disease · doi:10.14336/ad.2023.0530 · Cited by 24
“For more than three decades, APOE epsilon 4 has been recognized as solely adverse in terms of morbidity and mortality in the elderly [14, 15, 18, 99, 100], until the discovery of potentially superior health effects compared to APOE epsilon 3 [23, 101, 102], for example a higher vitamin D level in…”
BackgroundLipoprotein Particles in Cerebrospinal Fluid
Tsujita, M., Melchior, J. T., & Yokoyama, S. (2024) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.123.318284 · Cited by 24
(2002) · PubMed · Cited by 24
Newton, P., the BIOCARD Research Team, Tchounguen, J., Pettigrew, C., Lim, C., Lin, Z., Lu, H., Moghekar, A., Albert, M., & Soldan, A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220846 · Cited by 23
“between A 42 and WMH (both globally and regionally) may be stronger among carriers of the APOE 4 allele, the major genetic risk factor for late-onset AD [27], than among 4-non-carriers, as has been suggested by a few prior studies [17, but see 20, 28].”
ResultMicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease
Yoon, H., Flores, L. F., & Kim, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.04.020 · Cited by 29
“APOE4 allele increases the risk of developing AD, whereas APOE2 allele is protective [70, 71].”
BackgroundProtective ApoE variants support neuronal function by effluxing oxidized phospholipids
Ralhan, I., Do, A. D., Bae, J.-Y., Feringa, F. M., Cai, W., Chang, J., Chik, K., Lee, N. Y. J., Gerry, C. J., van der Kant, R., et al. (2026) · Neuron · doi:10.1016/j.neuron.2025.10.040 · Cited by 23
Zepa, L., Frenkel, M., Belinson, H., Kariv-Inbal, Z., Kayed, R., Masliah, E., & Michaelson, D. M. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/792070 · Cited by 23
“Genetic and epidemiological studies revealed that the allele ε4 of apoE is a strong genetic risk factor for early and late onset of Alzheimer’s disease (AD) [3, 4].”
BackgroundiPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype
Sullivan, M. A., Lane, S. D., McKenzie, A. D. J., Ball, S. R., Sunde, M., Neely, G. G., Moreno, C. L., Maximova, A., Werry, E. L., & Kassiou, M. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02951-2 · Cited by 23
“In humans, APOE presents as three allelic variants (APOE ε2, APOE ε3 and APOE ε4) and compared to individuals with the APOE ε3/ε3 genotype, the APOE ε3/ ε4 genotype confers around a threefold increase in risk of developing AD and is significantly overrepresented in individuals with sAD [71, 72].”
BackgroundWoody, S. K., Zhou, H., Ibrahimi, S., Dong, Y., & Zhao, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160307 · Cited by 23
“In contrast, ApoE4, occurring in 20% of the population, is present in nearly 50% of AD patients [16].”
BackgroundHigh-density lipoprotein-related cholesterol metabolism in Alzheimer's disease
Pedrini, S., Chatterjee, P., Hone, E., & Martins, R. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15170 · Cited by 22
“It is widely accepted that the presence of the allele ApoE4 is a major risk factor for late-onset AD and causes the onset of the disease at an earlier age (Corder et al., 1993; Strittmatter et al., 1993).”
BackgroundExploratory data from complete genomes of familial alzheimer disease age-at-onset outliers
Lalli, M. A., Garcia, G., Madrigal, L., Arcos-Burgos, M., Arcila, M. L., Kosik, K. S., & Lopera, F. (2012) · Human Mutation · doi:10.1002/humu.22167 · Cited by 19
“Seven genes contained both potential risk and protective variants, similar to APOE in which the ε4 allele is a risk factor and the ε2 allele is protective [Corder et al., 1993, 1994], potentially implicating these genes as molecular switches for the onset of the disease (Supp.”
BackgroundAPOE and vascular disease: Sequencing and genotyping in general population cohorts
Rasmussen, K. L., Luo, J., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117218 · Cited by 22
Valencia-Olvera, A. C., Balu, D., Faulk, N., Amiridis, A., Wang, Y., Pham, C., Avila-Munoz, E., York, J. M., Thatcher, G. R. J., & LaDu, M. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01375-3 · Cited by 22
Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease
Patra, K., Giannisis, A., Edlund, A. K., Sando, S. B., Lauridsen, C., Berge, G., Grøntvedt, G. R., Bråthen, G., White, L. R., & Nielsen, H. M. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190175 · Cited by 22
“Carriers of the (cid:2) 4 gene variant are known to harbor an increased risk of sporadic Alzheimer’s disease (AD) [2] whereas the (cid:2) 2 variant appears to be protective, and the (cid:2) 3 is considered to be neutral to the risk of AD [3, 4].”
Kitzlerová, E., Fišar, Z., Lelková, P., Jirák, R., Zvěřová, M., Hroudová, J., Manukyan, A., Martásek, P., & Raboch, J. (2018) · Medical Science Monitor · doi:10.12659/msm.907202 · Cited by 21
“Thus, the role of ApoE proteins in the pathophysiology of late-onset AD [128,129] was confirmed.”
BackgroundMa, C., Wang, J., Zhang, J., Chen, K., Li, X., Shu, N., Chen, Y., Liu, Z., & Zhang, Z. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0224-5 · Cited by 21
“The ε4 allele of the apolipoprotein E (APOE) gene is the best-known genetic risk factor for AD [1].”
BackgroundLi, X., Tang, X., Zeng, J., Duan, L., Hou, Z., Li, L., Guo, Y., Chai, C., Liu, J., Wang, Y., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.020 · Cited by 32
Greda, A. K., Gomes, J. P., Schmidt-Krueger, V., Zurawska-Plaksej, E., Fritsche-Guenther, R., Rudolph, I.-M., Telugu, N. S., Cömert, C., Kirwan, J., Kunz, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01389-5 · Cited by 21
“This observation is important as APOE ε4 represents the major genetic risk factor for sporadic Alzheimer disease, increasing disease risk in homozygous carriers by 12-fold as compared to carriers of the common APOE ε3/ε3 genotype 16 .”
Frikke-Schmidt, R., Sing, C., Nordestgaard, B., & Tybj�rg-Hansen, A. (2004) · Human Genetics · doi:10.1007/s00439-004-1165-z · Cited by 21
“Carriers of the ε4 allele are at increased risk for cardiovascular disease (CVD) and Alzheimer’s disease (Corder et al. 1993; Strittmatter et al. R. Frikke-Schmidt .”
BackgroundUnderstanding the Role of miR-33 in Brain Lipid Metabolism: Implications for Alzheimer's Disease
Jaouen, F., & Gascon, E. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4571-15.2016 · Cited by 21
A missense variant in SHARPIN mediates Alzheimer’s disease-specific brain damages
Park, J. Y., Lee, D., Lee, J. J., Gim, J., Gunasekaran, T. I., Choi, K. Y., Kang, S., Do, A. R., Jo, J., Park, J., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01680-5 · Cited by 21
Pathways linking Alzheimer’s disease risk genes expressed highly in microglia
Hodges, A. K., Piers, T. M., Collier, D., Cousins, O., & Pocock, J. M. (2021) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.60 · Cited by 21
“APOE has been convincingly associated with AD for nearly 30 years([188]), reflecting its very large contribution to AD risk.”
Fan, J., Stukas, S., Wong, C., Chan, J., May, S., DeValle, N., Hirsch-Reinshagen, V., Wilkinson, A., Oda, M. N., & Wellington, C. L. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014365 · Cited by 21
“Carriers of the apoE4 allele display increased AD prevalence and an earlier age of onset in a gene dose-dependent manner [23], whereas inheritance of the apoE2 allele delays the age of onset and reduces AD prevalence [24].”
BackgroundAssociation of hospitalization, critical illness, and infection with brain structure in older adults
Walker, K. A., Gottesman, R. F., Wu, A., Knopman, D. S., Mosley, T. H., Alonso, A., Kucharska‐Newton, A., & Brown, C. H. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15470 · Cited by 20
“21 Importantly, our findings were observed after adjusting for demographic and physiological variables, medical comorbidity, and APOE genotype, and remained after demented participants were excluded.”
BackgroundDo Microglia default on network maintenance in Alzheimer's disease?
Southam, K. A., Vincent, A. J., & Small, D. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151075 · Cited by 20
“An early discovery was that allelic variants of apolipoprotein E (ApoE) carry inherently different risks of AD [13–15].”
BackgroundGamache, J., Gingerich, D., Shwab, E. K., Barrera, J., Garrett, M. E., Hume, C., Crawford, G. E., Ashley-Koch, A. E., & Chiba-Falek, O. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01120-5 · Cited by 20
“The e4 allele of the apolipoprotein E gene ( APOE e4) was the first, strongest, and most firmly established genetic risk factor for LOAD [4–7].”
BackgroundVery low density lipoprotein receptor in Alzheimer disease
Helbecque, N., & Amouyel, P. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000815)50:4<273::aid-jemt4>3.0.co;2-0 · Cited by 20
Huber, G., März, W., Martin, J. R., Malherbe, P., Richards, J. G., Sueoka, N., Ohm, T., & Hoffmann, M. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00341-9 · Cited by 20
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.